Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Women's Health Therapeutics (Infection, Pregnancy, Oncology) Market Size, Share & Trends Analysis Report, 2018-2025 - ResearchAndMarkets.com

Research and Markets
Posted on: 01 Nov 18

The "Women's Health Therapeutics Market Size, Share & Trends Analysis Report By Type (Infection, Pregnancy, Oncology), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

The global women's health therapeutics market size is expected to reach USD 210.9 billion by 2025

It is anticipated to expand at a CAGR of 8.8% over the forecast period. Entry of effective drugs, a rise in awareness about early diagnosis and treatment, along with prevalence of chronic diseases are among the key factors likely to drive the market during the forecast period.

The women's health therapeutics market is expected to witness high growth in the forthcoming years due to increasing investment by key market players to fulfill demand in areas of infection, cancer, and pregnancy-related complications. In October 2016, Prelude Fertility, Inc. received USD 200 million from the Reproductive Biology Associates (RBA) and My Egg Bank North America (MEB) that focuses on providing fertility services and treatment to people with delayed childbirth. Juneau Biosciences, LLC has deployed USD 35 million until 2017 towards development of molecular diagnostics and therapeutics for endometriosis (uterus) conditions.

There is significant unmet need associated with treatment options for female sexual dysfunction. Currently, there are no Food and Drug Administration (FDA)-approved drugs for the treatment of female sexual dysfunction and many promising molecules are in late stage of development phase. Some of these molecules include LibiGel by BioSante Pharmaceuticals and Femprox by Apricus Bio, currently in Phase III and Phase II of clinical trials respectively in U.S.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope

Chapter 4 Women's Health Therapeutics Market: Type Estimates & Trend Analysis

Chapter 5 Women's Health Therapeutics Market: Regional Estimates & Trend Analysis

Chapter 6 Competitive Landscape

  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Novartis AG
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • Mylan N.V.
  • Sun Pharmaceutical
  • Sanofi
  • CooperSurgical, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/3ls2jl/global_womens?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005869/en/

Business Wire
www.businesswire.com

Last updated on: 01/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.